
## Barry T Rouse

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6620391/publications.pdf Version: 2024-02-01



RADDY T POUSE

#	Article	IF	CITATIONS
1	Natural regulatory T cells in infectious disease. Nature Immunology, 2005, 6, 353-360.	14.5	914
2	CD4+CD25+ T Cells Regulate Virus-specific Primary and Memory CD8+ T Cell Responses. Journal of Experimental Medicine, 2003, 198, 889-901.	8.5	478
3	Immunity and immunopathology to viruses: what decides the outcome?. Nature Reviews Immunology, 2010, 10, 514-526.	22.7	467
4	Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression. Journal of Virology, 2007, 81, 2545-2553.	3.4	431
5	CD4+CD25+ Regulatory T Cells Control the Severity of Viral Immunoinflammatory Lesions. Journal of Immunology, 2004, 172, 4123-4132.	0.8	310
6	Regulatory T cells in virus infections. Immunological Reviews, 2006, 212, 272-286.	6.0	246
7	Inhibition of Ocular Angiogenesis by siRNA Targeting Vascular Endothelial Growth Factor Pathway Genes. American Journal of Pathology, 2004, 165, 2177-2185.	3.8	226
8	Role of regulatory T cells during virus infection. Immunological Reviews, 2013, 255, 182-196.	6.0	195
9	Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. International Journal of Cancer, 1997, 70, 706-718.	5.1	178
10	Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process during the Pathogenesis of Herpetic Stromal Keratitis. Journal of Virology, 2001, 75, 9828-9835.	3.4	175
11	Early events in HSV keratitis—setting the stage for a blinding disease. Microbes and Infection, 2005, 7, 799-810.	1.9	169
12	Galectin-9/TIM-3 Interaction Regulates Virus-Specific Primary and Memory CD8+ T Cell Response. PLoS Pathogens, 2010, 6, e1000882.	4.7	150
13	Virological and Immunological Outcomes of Coinfections. Clinical Microbiology Reviews, 2018, 31, .	13.6	147
14	CD4 + CD25 + T Cells Regulate Vaccine-Generated Primary and Memory CD8 + T-Cell Responses against Herpes Simplex Virus Type 1. Journal of Virology, 2004, 78, 13082-13089.	3.4	139
15	Role of IL-17 and Th17 Cells in Herpes Simplex Virus-Induced Corneal Immunopathology. Journal of Immunology, 2011, 187, 1919-1930.	0.8	133
16	Regulatory Cells and Infectious Agents: Deltentes Cordiale and Contraire. Journal of Immunology, 2004, 173, 2211-2215.	0.8	125
17	Controlling Herpes Simplex Virus-Induced Ocular Inflammatory Lesions with the Lipid-Derived Mediator Resolvin E1. Journal of Immunology, 2011, 186, 1735-1746.	0.8	125
18	Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. Journal of Leukocyte Biology, 1997, 61, 125-132.	3.3	121

#	Article	IF	CITATIONS
19	Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes. European Journal of Immunology, 1996, 26, 161-165.	2.9	118
20	pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. Journal of Immunological Methods, 1991, 141, 157-163.	1.4	108
21	Immunopathogenesis of herpetic ocular disease. Immunologic Research, 1997, 16, 375-386.	2.9	103
22	Role of Tim-3/Galectin-9 Inhibitory Interaction in Viral-Induced Immunopathology: Shifting the Balance toward Regulators. Journal of Immunology, 2009, 182, 3191-3201.	0.8	103
23	Prime-Boost Immunization with DNA Vaccine: Mucosal Route of Administration Changes the Rules. Journal of Immunology, 2001, 166, 5473-5479.	0.8	102
24	DNA Vaccines â^' A Modern Gimmick or a Boon to Vaccinology?. Critical Reviews in Immunology, 1997, 17, 139-154.	0.5	100
25	Host-Directed Antiviral Therapy. Clinical Microbiology Reviews, 2020, 33, .	13.6	99
26	Herpesviruses: Harmonious Pathogens but Relevant Cofactors in Other Diseases?. Frontiers in Cellular and Infection Microbiology, 2018, 8, 177.	3.9	97
27	Role of miR-132 in Angiogenesis after Ocular Infection with Herpes Simplex Virus. American Journal of Pathology, 2012, 181, 525-534.	3.8	96
28	Control of Stromal Keratitis by Inhibition of Neovascularization. American Journal of Pathology, 2001, 159, 1021-1029.	3.8	94
29	Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. Journal of Clinical Investigation, 2002, 110, 1105-1111.	8.2	93
30	Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. International Immunology, 1995, 7, 679-688.	4.0	90
31	Pathogenesis of herpes stromal keratitis – A focus on corneal neovascularization. Progress in Retinal and Eye Research, 2013, 33, 1-9.	15.5	90
32	Host Defense Mechanisms Against Infectious Bovine Rhinotracheitis Virus: In Vitro Stimulation of Sensitized Lymphocytes by Virus Antigen. Infection and Immunity, 1974, 10, 681-687.	2.2	90
33	Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Experimental Eye Research, 2006, 82, 46-54.	2.6	89
34	T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19001-19006.	7.1	89
35	Bystander Activation Involving T Lymphocytes in Herpetic Stromal Keratitis. Journal of Immunology, 2001, 167, 2902-2910.	0.8	88
36	DNA containing CpG motifs induces angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8944-8949.	7.1	88

#	Article	IF	CITATIONS
37	Production of Key Molecules by Ocular Neutrophils Early After Herpetic Infection of the Cornea. Experimental Eye Research, 1998, 67, 619-624.	2.6	86
38	Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. Journal of Clinical Investigation, 2002, 110, 1105-1111.	8.2	86
39	Modulation of Immunity against Herpes Simplex Virus Infection via Mucosal Genetic Transfer of Plasmid DNA Encoding Chemokines. Journal of Virology, 2001, 75, 569-578.	3.4	82
40	Herpes keratitis in the absence of anterograde transport of virus from sensory ganglia to the cornea. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11462-11467.	7.1	80
41	Herpes Simplex Virus Replication-Induced Expression of Chemokines and Proinflammatory Cytokines in the Eye: Implications in Herpetic Stromal Keratitis. Journal of Interferon and Cytokine Research, 1998, 18, 681-690.	1.2	79
42	CXCR2â^'/â^'Mice Show Enhanced Susceptibility to Herpetic Stromal Keratitis: A Role for IL-6-Induced Neovascularization. Journal of Immunology, 2004, 172, 1237-1245.	0.8	79
43	Innate Recognition Network Driving Herpes Simplex Virus-Induced Corneal Immunopathology: Role of the Toll Pathway in Early Inflammatory Events in Stromal Keratitis. Journal of Virology, 2007, 81, 11128-11138.	3.4	78
44	Herpes Simplex Virus-Induced Keratitis: Evaluation of the Role of Molecular Mimicry in Lesion Pathogenesis. Journal of Virology, 2001, 75, 3077-3088.	3.4	75
45	Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. British Journal of Ophthalmology, 2012, 96, 3-9.	3.9	75
46	Interplay of Regulatory T Cell and Th17 Cells during Infectious Diseases in Humans and Animals. Frontiers in Immunology, 2017, 8, 341.	4.8	74
47	Lymphotoxin αâ^'/â^Mice Develop Functionally Impaired CD8+T Cell Responses and Fail to Contain Virus Infection of the Central Nervous System. Journal of Immunology, 2001, 166, 1066-1074.	0.8	70
48	Virus Infections and Host Metabolism—Can We Manage the Interactions?. Frontiers in Immunology, 2020, 11, 594963.	4.8	69
49	In Vitro-Generated Antigen-Specific CD4 <sup>+</sup> CD25 <sup>+</sup> Foxp3 <sup>+</sup> Regulatory T Cells Control the Severity of Herpes Simplex Virus-Induced Ocular Immunoinflammatory Lesions. Journal of Virology, 2008, 82, 6838-6851.	3.4	68
50	IL-17A Differentially Regulates Corneal Vascular Endothelial Growth Factor (VEGF)-A and Soluble VEGF Receptor 1 Expression and Promotes Corneal Angiogenesis after Herpes Simplex Virus Infection. Journal of Immunology, 2012, 188, 3434-3446.	0.8	68
51	Induction of Protective Immunity against Herpes Simplex Virus with DNA Encoding the Immediate Early Protein ICP 27. Viral Immunology, 1995, 8, 53-61.	1.3	67
52	In Vivo Kinetics of GITR and GITR Ligand Expression and Their Functional Significance in Regulating Viral Immunopathology. Journal of Virology, 2005, 79, 11935-11942.	3.4	66
53	Qa-1b and CD94-NKG2a Interaction Regulate Cytolytic Activity of Herpes Simplex Virus-Specific Memory CD8+ T Cells in the Latently Infected Trigeminal Ganglia. Journal of Immunology, 2006, 176, 1703-1711.	0.8	66
54	Anti-Inflammatory Effects of FTY720 against Viral-Induced Immunopathology: Role of Drug-Induced Conversion of T Cells to Become Foxp3+ Regulators. Journal of Immunology, 2008, 180, 7636-7647.	0.8	65

#	Article	IF	CITATIONS
55	Limitations and modifications of quantitative polymerase chain reaction. Journal of Immunological Methods, 1993, 165, 207-216.	1.4	64
56	Bystander activation of CD4+ T cells can represent an exclusive means of immunopathology in a virus infection. European Journal of Immunology, 1999, 29, 3674-3682.	2.9	64
57	Ocular Neovascularization Caused by Herpes Simplex Virus Type 1 Infection Results from Breakdown of Binding between Vascular Endothelial Growth Factor A and Its Soluble Receptor. Journal of Immunology, 2011, 186, 3653-3665.	0.8	62
58	Controlling Viral Immuno-Inflammatory Lesions by Modulating Aryl Hydrocarbon Receptor Signaling. PLoS Pathogens, 2011, 7, e1002427.	4.7	62
59	Mice Transgenic for IL-1 Receptor Antagonist Protein Are Resistant to Herpetic Stromal Keratitis: Possible Role for IL-1 in Herpetic Stromal Keratitis Pathogenesis. Journal of Immunology, 2004, 172, 3736-3744.	0.8	61
60	Molecular adjuvants for mucosal immunity. Immunological Reviews, 2004, 199, 100-112.	6.0	61
61	The Mouse Model and Understanding Immunity to Herpes Simplex Virus. Clinical Infectious Diseases, 1991, 13, S935-S945.	5.8	60
62	Regulatory T cells in health and disease. Journal of Internal Medicine, 2007, 262, 78-95.	6.0	60
63	Herpes simplex virus latency and the immune response. Current Opinion in Microbiology, 1998, 1, 430-435.	5.1	59
64	Critical Role of MicroRNA-155 in Herpes Simplex Encephalitis. Journal of Immunology, 2014, 192, 2734-2743.	0.8	59
65	Role of interferon-Î <sup>3</sup> in immunity to herpes simplex virus. Journal of Leukocyte Biology, 1996, 60, 528-532.	3.3	58
66	The role of antibody dependent cytotoxicity in recovery from herpesvirus infections. Cellular Immunology, 1976, 22, 182-186.	3.0	56
67	Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine, 2001, 19, 4685-4693.	3.8	56
68	HSV-1-Mediated Modulation of Cytokine Gene Expression in a Permissive Cell Line: Selective Upregulation of IL-6 Gene Expression. Virology, 1996, 219, 295-300.	2.4	55
69	Treg control of antimicrobial T cell responses. Current Opinion in Immunology, 2006, 18, 344-348.	5.5	55
70	IL-10 and Natural Regulatory T Cells: Two Independent Anti-Inflammatory Mechanisms in Herpes Simplex Virus-Induced Ocular Immunopathology. Journal of Immunology, 2008, 180, 6297-6306.	0.8	55
71	Natural Killer Cells as Novel Helpers in Anti-Herpes Simplex Virus Immune Response. Journal of Virology, 2008, 82, 10820-10831.	3.4	55
72	Galectin-1 Reduces the Severity of Herpes Simplex Virus-Induced Ocular Immunopathological Lesions. Journal of Immunology, 2012, 188, 4631-4643.	0.8	54

#	Article	IF	CITATIONS
73	Induction of CD8 T-Cell-Specific Systemic and Mucosal Immunity against Herpes Simplex Virus with CpG-Peptide Complexes. Journal of Virology, 2002, 76, 6568-6576.	3.4	52
74	Host defense mechanisms against infectious bovine rhinotracheitis virus. Cellular Immunology, 1975, 17, 43-56.	3.0	51
75	Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines. Vaccine, 1998, 16, 1103-1110.	3.8	51
76	Neuroprotectin D1 Reduces the Severity of Herpes Simplex Virus–Induced Corneal Immunopathology. , 2013, 54, 6269.		51
77	Comparison of the Antiviral Effects of 5-Methoxymethyl-deoxyuridine with 5-lododeoxyuridine, Cytosine Arabinoside, and Adenine Arabinoside. Antimicrobial Agents and Chemotherapy, 1975, 8, 643-650.	3.2	50
78	Codelivery of CCR7 Ligands as Molecular Adjuvants Enhances the Protective Immune Response against Herpes Simplex Virus Type 1. Journal of Virology, 2003, 77, 12742-12752.	3.4	49
79	Use of quantitative polymerase chain reaction to quantitate cytokine messenger RNA molecules. Molecular Immunology, 1992, 29, 1229-1236.	2.2	48
80	Influence of Galectin-9/Tim-3 Interaction on Herpes Simplex Virus-1 Latency. Journal of Immunology, 2011, 187, 5745-5755.	0.8	48
81	On the Role of Regulatory T Cells during Viral-Induced Inflammatory Lesions. Journal of Immunology, 2012, 189, 5924-5933.	0.8	48
82	Frontline Science: Aspirin-triggered resolvin D1 controls herpes simplex virus-induced corneal immunopathology. Journal of Leukocyte Biology, 2017, 102, 1159-1171.	3.3	48
83	Characterization of Surface Receptors on Bovine Leukocytes. International Archives of Allergy and Immunology, 1978, 56, 289-300.	2.1	47
84	Role of miR-155 in the Pathogenesis of Herpetic Stromal Keratitis. American Journal of Pathology, 2015, 185, 1073-1084.	3.8	46
85	Elucidating the protective and pathologic T cell species in the virus-induced corneal immunoinflammatory condition herpetic stromal keratitis. Journal of Leukocyte Biology, 2005, 77, 24-32.	3.3	45
86	The Plasticity and Stability of Regulatory T Cells during Viral-Induced Inflammatory Lesions. Journal of Immunology, 2017, 199, 1342-1352.	0.8	44
87	Neutrophils in Antiviral Immunity: Inhibition of Virus Replication by a Mediator Produced by Bovine Neutrophils. Journal of Infectious Diseases, 1980, 141, 223-232.	4.0	43
88	Mechanisms of pathogenesis in herpetic immunoinflammatory ocular lesions. Veterinary Microbiology, 2002, 86, 17-26.	1.9	41
89	Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes and Infection, 2003, 5, 571-578.	1.9	41
90	Protective and Pathological Roles of Virus-Specific and Bystander CD8+T Cells in Herpetic Stromal Keratitis. Journal of Immunology, 2004, 173, 7575-7583.	0.8	41

#	Article	IF	CITATIONS
91	Cytotoxic T Lymphocytes Annals of the New York Academy of Sciences, 1988, 532, 257-272.	3.8	40
92	Immunization with Chaperone-Peptide Complex Induces Low-Avidity Cytotoxic T Lymphocytes Providing Transient Protection against Herpes Simplex Virus Infection. Journal of Virology, 2002, 76, 136-141.	3.4	40
93	Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. Journal of Immunological Methods, 1992, 152, 237-243.	1.4	39
94	Herpetic stromal keratitis in the absence of viral antigen recognition. Cellular Immunology, 2002, 219, 108-118.	3.0	39
95	Herpetic eye disease: immunopathogenesis and therapeutic measures. Expert Reviews in Molecular Medicine, 2004, 6, 1-14.	3.9	39
96	Viruses and autoimmunity. Autoimmunity, 2006, 39, 71-77.	2.6	39
97	The Role of T Cells in Herpes Stromal Keratitis. Frontiers in Immunology, 2019, 10, 512.	4.8	39
98	The inflammasome NLRP3 plays a protective role against a viral immunopathological lesion. Journal of Leukocyte Biology, 2016, 99, 647-657.	3.3	37
99	Complement enhances antiviral antibody-dependent cell cytotoxicity. Nature, 1977, 266, 456-458.	27.8	36
100	Involvement of an ATP-Dependent Peptide Chaperone in Cross-Presentation After DNA Immunization. Journal of Immunology, 2000, 165, 750-759.	0.8	36
101	Manipulating Glucose Metabolism during Different Stages of Viral Pathogenesis Can Have either Detrimental or Beneficial Effects. Journal of Immunology, 2017, 199, 1748-1761.	0.8	36
102	The Role of the Innate Immune System in the Reconstituted SCID Mouse Model of Herpetic Stromal Keratitis. Clinical Immunology and Immunopathology, 1996, 80, 23-30.	2.0	35
103	Chemokines and ocular pathology caused by corneal infection with herpes simplex virus. Journal of NeuroVirology, 1999, 5, 42-47.	2.1	35
104	Virus-Induced Immunopathology. Advances in Virus Research, 1996, 47, 353-376.	2.1	34
105	Pathogenesis of Herpes Simplex Virus-Induced Ocular Immunoinflammatory Lesions in B-Cell-Deficient Mice. Journal of Virology, 2000, 74, 3517-3524.	3.4	34
106	Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity. Journal of Leukocyte Biology, 2005, 78, 178-186.	3.3	33
107	Application of Plasmid DNA Encoding IL-18 Diminishes Development of Herpetic Stromal Keratitis by Antiangiogenic Effects. Journal of Immunology, 2005, 175, 509-516.	0.8	33
108	Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation. Journal of Experimental Medicine, 2010, 207, 2355-2367.	8.5	33

#	Article	IF	CITATIONS
109	TNFRSF25 Agonistic Antibody and Galectin-9 Combination Therapy Controls Herpes Simplex Virus-Induced Immunoinflammatory Lesions. Journal of Virology, 2012, 86, 10606-10620.	3.4	33
110	An improved method of loading pH-sensitive liposomes with soluble proteins for class I restricted antigen presentation. Journal of Immunological Methods, 1991, 145, 143-152.	1.4	32
111	Immune responses to viruses. , 2008, , 421-431.		32
112	Modulation of Viral Immunoinflammatory Responses with Cytokine DNA Administered by Different Routes. Journal of Virology, 1998, 72, 5545-5551.	3.4	32
113	Interferon Produced Endogenously in Response to CSF-1 Augments the Functional Differentiation of Progeny Macrophages. Journal of Leukocyte Biology, 1985, 37, 659-664.	3.3	31
114	Modulation of Mucosal and Systemic Immunity by Enteric Administration of Nonreplicating Herpes Simplex Virus Expressing Cytokines. Virology, 1998, 240, 245-253.	2.4	31
115	Why do we lack an effective vaccine against herpes simplex virus infections?. Microbes and Infection, 2000, 2, 973-978.	1.9	31
116	Viruses and autoimmunity: an affair but not a marriage contract. Reviews in Medical Virology, 2002, 12, 107-113.	8.3	31
117	MHC II-restricted, CD4+ cytotoxic T lymphocytes specific for herpes simplex virus-1: Implications for the development of herpetic stromal keratitis in mice. Clinical Immunology and Immunopathology, 1991, 61, 398-409.	2.0	30
118	Immune Modulation by IL-10 Gene Transfer via Viral Vector and Plasmid DNA: Implication for Gene Therapy. Cellular Immunology, 1999, 194, 194-204.	3.0	30
119	Induction of arginases I and II in cornea during herpes simplex virus infection. Virus Research, 2001, 73, 177-182.	2.2	30
120	Dual Role of B Cells in Mediating Innate and Acquired Immunity to Herpes Simplex Virus Infections. Cellular Immunology, 2000, 202, 79-87.	3.0	29
121	Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. Journal of Leukocyte Biology, 2004, 76, 868-875.	3.3	29
122	Heat-shock protein 70 acts as an effective adjuvant in neonatal mice and confers protection against challenge with Herpes Simplex Virus. Vaccine, 2005, 23, 3526-3534.	3.8	29
123	Human neutrophil – mediated destruction of antibody sensitized herpes simplex virus type I infected cells. Canadian Journal of Microbiology, 1978, 24, 182-186.	1.7	28
124	A Tale of Two Â-Herpesviruses: Lessons for Vaccinologists. Clinical Infectious Diseases, 2006, 42, 810-817.	5.8	28
125	Advantages of Foxp3 <sup>+</sup> regulatory T cell depletion using DEREG mice. Immunity, Inflammation and Disease, 2014, 2, 162-165.	2.7	28
126	Azacytidine Treatment Inhibits the Progression of Herpes Stromal Keratitis by Enhancing Regulatory T Cell Function. Journal of Virology, 2017, 91, .	3.4	28

#	Article	IF	CITATIONS
127	Toll-like receptor ligand links innate and adaptive immune responses by the production of heat-shock proteins. Journal of Leukocyte Biology, 2003, 73, 574-583.	3.3	27
128	An Anti-Inflammatory Role of VEGFR2/Src Kinase Inhibitor in Herpes Simplex Virus 1-Induced Immunopathology. Journal of Virology, 2011, 85, 5995-6007.	3.4	27
129	Determinants of Tissue-Specific Metabolic Adaptation of T Cells. Cell Metabolism, 2020, 32, 908-919.	16.2	27
130	Bovine Type II Interferon: Activity in Heterologous Cells. Intervirology, 1977, 8, 250-256.	2.8	26
131	Vaccination with the Immediate-Early Protein ICP47 of Herpes Simplex Virus-Type 1 (HSV-1) Induces Virus-Specific Lymphoproliferation, but Fails to Protect against Lethal Challenge. Virology, 1994, 200, 236-245.	2.4	26
132	Concomitant Helper Response Rescues Otherwise Low Avidity CD8+ Memory CTLs to Become Efficient Effectors In Vivo. Journal of Immunology, 2004, 172, 3719-3724.	0.8	26
133	Role of Inflammatory Cytokine-Induced Cycloxygenase 2 in the Ocular Immunopathologic Disease Herpetic Stromal Keratitis. Journal of Virology, 2005, 79, 10589-10600.	3.4	26
134	Enhanced viral immunoinflammatory lesions in mice lacking IL-23 responses. Microbes and Infection, 2008, 10, 302-312.	1.9	26
135	Control of Herpetic Stromal Keratitis Using CTLA4lg Fusion Protein. Clinical Immunology and Immunopathology, 1998, 86, 88-94.	2.0	25
136	Application of the Intracellular Gamma Interferon Assay To Recalculate the Potency of CD8+ T-Cell Responses to Herpes Simplex Virus. Journal of Virology, 2000, 74, 5709-5711.	3.4	25
137	IL-12 suppresses the expression of ocular immunoinflammatory lesions by effects on angiogenesis. Journal of Leukocyte Biology, 2002, 71, 469-76.	3.3	25
138	Polymorph-mediated antibody-dependent cytotoxicity—modulation of activity by drugs and immune interferon. Canadian Journal of Microbiology, 1976, 22, 1222-1228.	1.7	24
139	Cytotoxic T lymphocytes in herpesvirus infections. Veterinary Immunology and Immunopathology, 1984, 6, 35-66.	1.2	24
140	Protection by minigenes: a novel approach of DNA vaccines. Vaccine, 1998, 16, 1660-1667.	3.8	24
141	Herpes virus entry mediator (HVEM) modulates proliferation and activation of regulatory T cells following HSV-1 infection. Microbes and Infection, 2014, 16, 648-660.	1.9	24
142	Depletion of MCP-1 increases development of herpetic stromal keratitis by innate immune modulation. Journal of Leukocyte Biology, 2006, 80, 1405-1415.	3.3	23
143	Tregs and infections: on the potential value of modifying their function. Journal of Leukocyte Biology, 2011, 90, 1079-1087.	3.3	23
144	Frequency of Cytotoxic T Lymphocyte Precursors to Herpes Simplex Virus Type 1 as Determined by Limiting Dilution Analysis. Infection and Immunity, 1983, 39, 785-792.	2.2	23

#	Article	IF	CITATIONS
145	Interactions between Effector Cell Activity and Lymphokines: Implications for Recovery from Herpesvirus Infections. International Archives of Allergy and Immunology, 1978, 57, 62-73.	2.1	22
146	Apparent Requirement for CD4 <sup>+</sup> T Cells in Primary Anti-Herpes Simplex Virus Cytotoxic T-Lymphocyte Induction Can Be Overcome by Optimal Antigen Presentation. Viral Immunology, 1991, 4, 177-186.	1.3	22
147	Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology, 2005, 331, 151-158.	2.4	22
148	Supplementing the Diet with Sodium Propionate Suppresses the Severity of Viral Immuno-inflammatory Lesions. Journal of Virology, 2021, 95, .	3.4	22
149	Gal power: the diverse roles of galectins in regulating viral infections. Journal of General Virology, 2019, 100, 333-349.	2.9	22
150	Plasmid DNA Encoding CCR7 Ligands Compensate for Dysfunctional CD8+ T Cell Responses by Effects on Dendritic Cells. Journal of Immunology, 2001, 167, 3592-3599.	0.8	21
151	On the role of retinoic acid in virus induced inflammatory response in cornea. Microbes and Infection, 2018, 20, 337-345.	1.9	21
152	Does the hygiene hypothesis apply to COVID-19 susceptibility?. Microbes and Infection, 2020, 22, 400-402.	1.9	21
153	Role of Coexpression of IL-2 and Herpes Simplex Virus Proteins in Recombinant Vaccinia Virus Vectors on Levels of Induced Immunity. Viral Immunology, 1990, 3, 207-215.	1.3	20
154	Immunological Memory. Immunological Reviews, 2006, 211, 5-7.	6.0	19
155	Regulatory T cells and immunity to pathogens. Expert Opinion on Biological Therapy, 2007, 7, 1301-1309.	3.1	19
156	Functional T Cell Recognition of Synthetic Peptides Corresponding to Continuous Antibody Epitopes of Herpes Simplex Virus Type 1 Glycoprotein D. Immunobiology, 1988, 177, 134-148.	1.9	18
157	Resistance to Herpetic Stromal Keratitis in Immunized B-Cell-Deficient Mice. Virology, 1999, 257, 168-176.	2.4	18
158	Blocking Mouse MMP-9 Production in Tumor Cells and Mouse Cornea by Short Hairpin (sh) RNA Encoding Plasmids. Oligonucleotides, 2005, 15, 72-84.	2.7	18
159	Are miRNAs critical determinants in herpes simplex virus pathogenesis?. Microbes and Infection, 2018, 20, 461-465.	1.9	18
160	Application of our understanding of pathogenesis of herpetic stromal keratitis for novel therapy. Microbes and Infection, 2018, 20, 526-530.	1.9	18
161	Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects. Journal of Immunology, 2006, 177, 4122-4131.	0.8	17
162	Did Climate Change Influence the Emergence, Transmission, and Expression of the COVID-19 Pandemic?. Frontiers in Medicine, 2021, 8, 769208.	2.6	17

#	Article	IF	CITATIONS
163	Depression of Humoral Antibody Formation in the Chicken by Thymectomy and Antilymphocyte Serum. Nature: New Biology, 1972, 236, 79-80.	4.5	16
164	Quantitative studies on CD4+ and CD8+ cytotoxic T lymphocyte responses against herpes simplex virus type 1 in normal and β2-m deficient mice. Immunobiology, 1994, 190, 183-194.	1.9	16
165	In vivo rescue of defective memory CD8 + T cells by cognate helper T cells. Journal of Leukocyte Biology, 2005, 78, 879-887.	3.3	16
166	Activation of Endothelial Roundabout Receptor 4 Reduces the Severity of Virus-Induced Keratitis. Journal of Immunology, 2011, 186, 7195-7204.	0.8	16
167	Factors Affecting the Tissue Damaging Consequences of Viral Infections. Frontiers in Microbiology, 2019, 10, 2314.	3.5	16
168	Macrophage IL-12p70 Signaling Prevents HSV-1–Induced CNS Autoimmunity Triggered by Autoaggressive CD4+Tregs. , 2011, 52, 2321.		15
169	How host metabolism impacts on virus pathogenesis. Current Opinion in Virology, 2018, 28, 37-42.	5.4	15
170	Role of IL-18 induced Amphiregulin expression on virus induced ocular lesions. Mucosal Immunology, 2018, 11, 1705-1715.	6.0	15
171	Role of Ia Antigen Expression and Secretory Function of Accessory Cells in the Induction of Cytotoxic T Lymphocyte Responses Against Herpes Simplex Virus. Infection and Immunity, 1982, 37, 1138-1147.	2.2	15
172	Lymphocyte Activation by Cell Separation Procedures. Immunological Investigations, 1976, 5, 637-648.	0.8	14
173	Influence of CCR7 ligand DNA preexposure on the magnitude and duration of immunity. Virology, 2003, 312, 169-180.	2.4	14
174	Role of Stat4-Mediated Signal Transduction Events in the Generation of Aggressor CD4+T Cells in Herpetic Stromal Keratitis Pathogenesis. Journal of Interferon and Cytokine Research, 2007, 27, 65-75.	1.2	14
175	Potential Function of miRNAs in Herpetic Stromal Keratitis. , 2013, 54, 563.		14
176	Robo 4 Counteracts Angiogenesis in Herpetic Stromal Keratitis. PLoS ONE, 2015, 10, e0141925.	2.5	14
177	Dysregulation of cytokine expression in monocytes from HIV-positive individuals. Journal of Leukocyte Biology, 1994, 56, 347-352.	3.3	13
178	Control of viral immunoinflammatory lesions by manipulating CD200:CD200 receptor interaction. Clinical Immunology, 2009, 131, 31-40.	3.2	13
179	Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections. Expert Opinion on Biological Therapy, 2001, 1, 213-225.	3.1	12
180	Antigenic peptides complexed to phylogenically diverse Hsp70s induce differential immune responses. Cell Stress and Chaperones, 2003, 8, 134.	2.9	12

#	Article	IF	CITATIONS
181	Climate change: how it impacts the emergence, transmission, resistance and consequences of viral infections in animals and plants. Critical Reviews in Microbiology, 2021, 47, 307-322.	6.1	11
182	Controlling herpetic stromal keratitis by modulating lymphotoxin-alpha-mediated inflammatory pathways. Microbes and Infection, 2013, 15, 677-687.	1.9	10
183	Immunopathology of Herpesvirus Infections. , 1985, , 103-119.		10
184	Modulating glutamine metabolism to control viral immuno-inflammatory lesions. Cellular Immunology, 2021, 370, 104450.	3.0	10
185	Regulation of Microbial Immunity: The Suppressor Cell Renaissance. Viral Immunology, 2005, 18, 411-418.	1.3	9
186	A strategy for selective, CD4+ T cell-independent activation of virus-specific memory B cells for limiting dilution analysis. Journal of Immunological Methods, 2006, 313, 110-118.	1.4	9
187	Hexokinase II may be dispensable for CD4 T cell responses against a virus infection. PLoS ONE, 2018, 13, e0191533.	2.5	9
188	Could targeting immunometabolism be a way to control the burden of COVID-19 infection?. Microbes and Infection, 2021, 23, 104780.	1.9	9
189	Inhibiting Glucose Metabolism Results in Herpes Simplex Encephalitis. Journal of Immunology, 2021, 207, 1824-1835.	0.8	9
190	EQUINE INFLUENZA IMMUNISATION—THE ROLE OF NASAL ANTIBODY—A REVIEW. Australian Veterinary Journal, 1971, 47, 146-148.	1.1	8
191	Immune Responsiveness of Lymphotoxin-α-Deficient Mice: Two Reconstitution Models. Cellular Immunology, 1998, 189, 116-124.	3.0	8
192	An intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virus. Hum Vaccin, 2008, 4, 360-364.	2.4	8
193	IL-2 complex treatment amplifies CD8+ T cell mediated immunity following herpes simplex virus-1 infection. Microbes and Infection, 2016, 18, 735-746.	1.9	8
194	Mechanisms of Viral Immunopathology. Advances in Veterinary Medicine, 1979, 23, 103-136.	0.1	8
195	The Proportion of Herpes Simplex Virus-Specific Cytotoxic T Lymphocytes (Tc) That Recognize Glycoprotein C Varies between Individual Mice and Is Dependent on the Form of Immunization. Viral Immunology, 1993, 6, 21-33.	1.3	7
196	Application of FGF-2 to Modulate Herpetic Stromal Keratitis. Current Eye Research, 2006, 31, 1021-1028.	1.5	7
197	Herpetic keratitis. , 2010, , 91-97.		7
198	COVID-19: disease, or no disease? - that is the question. It's the dose stupid!. Microbes and Infection, 2021, 23, 104779.	1.9	7

#	Article	lF	CITATIONS
199	DNA containing bioactive CpG motifs promote angiogenesis. Drug News and Perspectives, 2002, 15, 358.	1.5	7
200	Controlling the Burden of COVID-19 by Manipulating Host Metabolism. Viral Immunology, 2022, 35, 24-32.	1.3	7
201	The effect of the antiherpesvirus drug 5-methoxymethyl-2′-deoxyuridine on the humoral immune response in vivo. Canadian Journal of Microbiology, 1977, 23, 1059-1061.	1.7	6
202	Efficacy of the Herpes Simplex Virus Types 1 and 2 Mutant Viruses to Confer Protection against Zosteriform Spread in Mice. Viral Immunology, 1993, 6, 35-42.	1.3	6
203	Quantitative analysis of herpes simplex virus type 1-specific memory B cells generated by different routes of infection. Virology, 2007, 360, 136-142.	2.4	6
204	Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology. Frontiers in Immunology, 2020, 11, 581076.	4.8	6
205	Some unmet challenges in the immunology of viral infections. Discovery Medicine, 2010, 10, 363-70.	0.5	6
206	Virus-Induced Immunosuppression. Veterinary Clinics of North America - Small Animal Practice, 1986, 16, 1097-1127.	1.5	5
207	Viruses and autoimmunity. Autoimmunity, 2005, 38, 559-565.	2.6	5
208	A novel flow cytometry based assay for quantification of corneal angiogenesis in the mouse model of herpetic stromal keratitis. Experimental Eye Research, 2005, 80, 73-81.	2.6	5
209	HSV: immunopathological aspects of HSV infection. , 0, , 642-655.		5
210	An Approach to Control Relapse of Inflammatory Lesions after Discontinuation of Primary Therapy. PLoS ONE, 2014, 9, e98051.	2.5	5
211	DNA Vaccines – A Modern Gimmick or a Boon to Vaccinology?. Critical Reviews in Immunology, 2017, 37, 483-498.	0.5	5
212	Host Defenses to Viruses. , 2019, , 365-374.e1.		5
213	Controlling Herpes Simplex Virus-Induced Immunoinflammatory Lesions Using Metabolic Therapy: a Comparison of 2-Deoxy- <scp>d</scp> -Glucose with Metformin. Journal of Virology, 0, , .	3.4	5
214	DNA vaccines for the prophylaxis and modulation of HSV infections. Expert Opinion on Investigational Drugs, 1998, 7, 219-224.	4.1	4
215	Waking up T cells to counteract chronic infections. Trends in Immunology, 2006, 27, 205-207.	6.8	4
216	miR-31: a key player in CD8 T-cell exhaustion. Cellular and Molecular Immunology, 2017, 14, 954-956.	10.5	4

#	Article	IF	CITATIONS
217	Fraternal Twins: The Enigmatic Role of the Immune System in Alphaherpesvirus Pathogenesis and Latency and Its Impacts on Vaccine Efficacy. Viruses, 2022, 14, 862.	3.3	4
218	Herpesvirus vaccines. Advanced Drug Delivery Reviews, 1996, 21, 63-76.	13.7	3
219	Homeostatic expansion of CD4+ T cells upregulates VLA-4 and exacerbates HSV-induced corneal immunopathology. Microbes and Infection, 2008, 10, 1192-1200.	1.9	3
220	Non-mitogenic Anti-CD3F(ab′)2Monoclonal Antibody: A Novel Approach to Control Herpetic Stromal Keratitis. , 2008, 49, 5425.		3
221	The Control of Human Herpesvirus Infections by Cytotoxic T Lymphocytes(CTL): A Comparison to AIDS Virus Specific CTL. , 1990, , 73-98.		3
222	On the Mechanisms of T Cell Silencing by IL-10 DNA: Direct and Indirect Inhibition of T Cell Functions. Cellular Immunology, 2000, 206, 59-69.	3.0	2
223	Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. , 1997, 70, 706.		2
224	Host-microbe interactions: fungi/viruses/parasites. Current Opinion in Microbiology, 1999, 2, 343-347.	5.1	1
225	Regulation of Antimicrobial Immunity. , 0, , 109-120.		1
226	Some vexations that challenge viral immunology. F1000Research, 2016, 5, 1015.	1.6	1
227	Host defenses to viruses. , 2013, , 346-355.		1
228	Virus-Induced Immunosuppression. , 1996, , 131-156.		1
229	Acquired Immunity against Virus Infections. , 0, , 237-254.		1
230	DNA Vaccines Against Herpesviruses. , 2003, , 126-140.		0
231	Immune Responses to Persistent Viruses. , 0, , 255-267.		0
232	Antiviral Cytotoxic T-Lymphocytes and Vaccines. , 1989, , 239-266.		0
233	Pathology and Pathogenesis of Virus Infections. , 0, , 383-389.		0